Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Debt / NOTE 3.250%11/0
-
Market price (% of par)
-
95.0%
-
Total 13F principal
-
$213,885,735
-
Principal change
-
+$9,156,659
-
Total reported market value
-
$228,859,000
-
Number of holders
-
19
-
Value change
-
+$9,277,508
-
Number of buys
-
4
-
Number of sells
-
3
Institutional Holders of THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 as of Q1 2022
As of 31 Mar 2022,
THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 was held by
19 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$213,885,735
in principal (par value) of the bond.
The largest 10 bondholders included
HBK INVESTMENTS L P, DeepCurrents Investment Group LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, BAUPOST GROUP LLC/MA, AVIVA PLC, Maven Securities LTD, Aequim Alternative Investments LP, Verition Fund Management LLC, OAKTREE CAPITAL MANAGEMENT LP, and TENOR CAPITAL MANAGEMENT Co., L.P..
This page lists
19
institutional bondholders reporting positions
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.